Follows adults with atrial fibrillation treated with the PulseSelect PFA System
Follows adults with atrial fibrillation who receive the PulseSelect PFA System.
Plain-language title generated from the registry record
Registry title: PulseSelect™ PFA Global Registry
Key facts
- Where
- Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, Ürümqi, Wuhan, Xiamen, and Zhengzhou, ChinaSee the 11 sites
Where in China
- Fuwai Hospital Chinese Academy of Medical SciencesBeijing, ChinaNo longer taking part
- Fujian Provincial HospitalFuzhou, ChinaNo longer taking part
- The Second Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNo longer taking part
- The First Peoples Hospital of Yunnan ProvinceKunming, ChinaNo longer taking part
- Nanjing Drum Tower hospitalNanjing, ChinaNo longer taking part
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaNo longer taking part
- Fuwai Shenzhen Hospital Chinese Academy of Medical SciencesShenzhen, ChinaNo longer taking part
- The First Affiliated Hospital of Xinjiang Medical UniversityÜrümqi, ChinaNo longer taking part
- Wuhan Asia General HospitalWuhan, ChinaNo longer taking part
- The First Affiliated hospital of Xiamen UniversityXiamen, ChinaNo longer taking part
- Fuwai Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeZhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medtronic Cardiac Ablation Solutions
- Trial code
- NCT06393920
- Record updated
- 16 October 2026
- Original description
The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.Read full original descriptionShow less
PulseSelect PFA Global Registry, a Part of the Medtronic Cardiac Ablation Post-Market Study Platform
The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.
Inclusion: Subject is ≥ 18 years of age or minimum age as required by local regulations; Subject has been diagnosed with atrial fibrillation (AF); Planned procedure using commercially available PulseSelect™ PFA System; Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements.
Exclusion: Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager; Subject with exclusion criteria required by local law.